A fourth dose of DTPa-IPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11-12 months of age

Scandinavian Journal of Infectious Diseases

Volumn 37, Issue 3, 2005, Pages 221-229

  Nilsson, Lennart ^a   Faldella, Giacomo ^b   Jacquet, Jeanne Marie ^c   Storsaeter, Jann ^d   Silfverdal, Sven Arne ^e   Ekholm, Leif ^f  

^a Children's Research Department   (Sweden)

^b Ist Clin Pediat Prevent/Neonatol   (Italy)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

^d GLAXOSMITHKLINE   (United Kingdom)

^e Paediatric University Clinic   (Sweden)

^f Child Health Care Unit   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPLOID CELL VACCINE; INFANRIX IPV; POLIOMYELITIS VACCINE;

ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DROWSINESS; DRUG DOSE REGIMEN; EDEMA; FEMALE; FEVER; FRACTURE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION PAIN; ITALY; MALE; PERTUSSIS; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SWEDEN; TETANUS; VIRUS INFECTION;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; ITALY; MALE; POLIOVIRUS VACCINE, INACTIVATED; SWEDEN; VACCINES, COMBINED;

EID: 14944362390     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540410020884     Document Type: Article

References (31)

1. Olin P, Gustafsson L, Barreto L, Hessel L, Mast T, Rie A, et al. Declining pertussis incidence in Sweden following the introduction of acellular vaccine. Vaccine 2003;21:2015-21.
2. van der Wielen M, van Damme P, van Herck K, Schlegel-Haueter S, Siegrist C-A. Seroprevalence of Bordetella pertussis antibodies in Flanders (Belgium). Vaccine 2003;21: 2412-7.
3. Cattaneo L, Reed G, Haase D, Wills M, Edwards K. The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1-65 y. J Infect Dis 1996;173:1256-9.
4. Torvaldsen S, Hull B, McIntyre P. Using the Australian Childhood Immunisation Register to track the transition from whole-cell to acellular pertussis vaccines. Commun Dis Intell 2002;26:581-3.
5. He Q, Viljanen M, Arvilommi H, Aittanen B, Mertsola J. Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population. J Am Med Assoc 1998;280:635-7.
6. Skowronski D, De Serres G, MacDonald D, Wu W, Shaw C, Macnabb J, et al. The changing age and seasonal profile of pertussis in Canada. J Infect Dis 2002;185:1448-53.
7. Campins-Marti M, Cheng HK, Forsyth K, Guiso N, Halperin S, Huang LM, et al. and International Consensus Group on Pertussis Immunisation. Recommendations are needed for adolescent and adult pertussis immunization: rationale and strategies for consideration. Vaccine 2002;20: 641-6.
8. Therre H, Baron S. Pertussis surveillance in Europe: the situation in late 1999. Eurosurveillance Monthly Archives 2000; 5(1). Available from: URL http://www.eurosurveillance.org/em/v05n01/0501-223.asp
9. Anderson P. Danish childhood vaccination programme modified to include pertussis and polio boosters at 5 y of age. Eurosurveillance Weekly archives 2003; 7(35). Available from: URL http://www.eurosurveillance.org/ew/index.asp?lg=&an=2003
10. Gibbons V. Addition of acellular pertussis to preschool booster in the United Kingdom. Eurosurveillance Weekly archives 2001;5(46). Available from: URL http://www.eurosurveillance.org/ew/2001/011115.asp
11. Institut pour le Développement de l'Epidémiologie Appliquée. Calendrier vaccinal 1998: Bulletin Epidémiologique hebdomadaire(BEH) 1998;15.
12. Impfempfehlungen der ständigen impfkom-mission (STIKO) am Robert Koch-Institut. Stand: Jan 2000. Dt. Ärzteblatt 2000;16(Suppl):3-18.
13. Miyamura K, Nisho S, Ito A, Murato R, Kono R. Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells: I. Studies on factors affecting the toxin and antitoxin titration. J Biol Stand 1974;2:189-201.
14. Miyamura K, Nisho S, Ito A, Murata R, Kono R. Micro cell culture method for determination of diphtheria toxin and antitoxin titres using VERO cells: II. Comparison with rabbit skin method and practical application for seroepidemiological studies. J Biol Stand 1974;2:203-9.
15. Melville-Smith M, Seagroatt V, Watkins J. A comparison of an enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand 1983;11:137-44.
16. World Health Organization. Guidelines for WHO/EPI collaborative studies on poliomyelitis. Standard procedure for determining immunity to poliovirus using the microneutralization test. Expanded Programme on Immunization General Distribution. WHO/EPI/GEN 93.9:1-26.
17. World Health Organization. Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in the Gambia, Oman and Thailand. Bulletin of the World Health Organization, 1996;74:253-68.
18. Miettinen O, Nurlminen M. Comparative analysis of two rates. Stat Med 1985;4:213-66.
19. Camargo M, Silveira L, Furuta J, Oliveira E, Germek O. Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. J Clin Microbiol 1984;20:772-4.
20. Skogen V, Jenum P, Koroleva V, Danilova E, Halvorsen DS, Maksimova N, Sjursen H. Detection of diphtheria antitoxin by four different methods. Clin Microbiol Infect 1999;5: 628-33.
21. Schmitt H, Beutel K, Schuind A, Knuf M, Wagner S, Muschenborn S, et al. Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age. J Pediatr 1907;130:616-23.
22. Rennels M, Deloria M, Pichichero M, Losonsky GA, Englund JA, Meade BD, et al. Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 2000;105:e12. www.pediatrics.org/cgi/content/full/105/1/e12
23. Tozzi A, Anemona A, Stefanelli P, Salmaso S, Atti ML, Mastrantonio P, Giammanco A, and the Progetto Pertosse Study Group. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines. Pediatrics 2001;107:1-9.
24. Pichichero M, Edwards K, Anderson E, Rennels MB, Englund JA, Yerg DE, et al. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year old children. Pediatrics 2000;105:1-8.
25. Skowronski D, Remple V, Macnabb J, Pielak K, Patrick D, Halperin S, Scheifele D. Injection-site reactions to booster doses of acellular pertussis vaccine: rate, severity, and anticipated impact. Pediatrics 2003;112:e453-9.
26. Halperin S, Eastwood B, Barreto L, Friesen B, Medd L, Meekison W, Guasparini R. Adverse reactions and antibody response to four doses of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life. Vaccine 1996;14:767-72.
27. Halperin S, Scheifele D, Barreto L, Pim C, Guasparini R, Medd L, et al. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age. Pediatr Infect Dis J 1999;18:772-9.
28. Halperin S, Scheifele D, Mills E, Guasparini R, Humphreys G, Barreto L, Smith B. Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine. Vaccine 2003;21:2298-306.
29. Vitek C, Brennan M, Gotway C, Bragina V, Govorukina N, Kravstova O, et al. Risk of diphtheria among school children in the Russian Federation in relation to time since last vaccination. Lancet 1999;353:355-8.
30. Skogen V, Jenum P, Danilov E, Korolev V, Halvorsen D, Sjursen H. Immunity to diphtheria among children in Northern Norway and North-Western Russia. Vaccine 2000;19:197-203.
31. Edmunds W, Pebody R, Aggerback H, Baron S, Berbers G, Conyn-van Spaendonck MA, et al. The sero-epidemiology of diphtheria in Western Europe. Epidemiol Infect 2000;125: 113-25.